AGL - Agilon Health continues post-IPO rally amid contrasting views

marrio31/iStock via Getty Images Healthcare service provider agilon health (AGL) has climbed ~88.0% since its public debut in April. While Wall Street analysts are overly bullish on the stock, Seeking Alpha Author’s ratings remain neutral. Last month, several Street analysts initiated the coverage of agilon with buy-equivalent ratings. Bank of America analysts led by Kevin Fischbeck estimated a price target of $41.00 and called it “a high-growth physician practice management company,” However, Seeking Alpha contributor Alejandro Arrieche argues that “its growth is progressively slowing down.” Unless the management takes steps to reverse the trend, it “will not reach profitability in the near future,” Arrieche wrote in a neutral thesis on the stock. Another SA contributor, The Value Investor is also neutral on agilon pointing out that “despite the ambitions of the company in its huge addressable market,” the valuation at 10x “is a huge multiple given the limited gross margin (potential) of the company.” However,

For further details see:

Agilon Health continues post-IPO rally amid contrasting views